



Voyager Therapeutics Added to Russell 2000®, 3000® and Global Indexes

12/18/15

CAMBRIDGE, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it has been added to the Russell 2000®, Russell 3000® and Russell Global® Indexes as part of Russell Investments' quarterly addition of select initial public offering (IPO) companies. Voyager will join these indexes after the NASDAQ market closes on December 18, 2015.

The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10% of the total market capitalization of that index. Membership in the Russell 2000® Index includes automatic inclusion in the appropriate growth and style indexes.

Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Russell Investments determines membership for each index based on objective market capitalization rankings and style attributes. More than \$5.7 trillion in assets are currently benchmarked to the Russell family of indexes.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company's pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on [LinkedIn](#).

Contact: □

Investor Relations:

Sarah McCabe

Stern Investor Relations, Inc.

212-362-1200 □

sarah@sternir.com

Media: □

Katie Engleman

Pure Communications, Inc.

910-509-3977 □

Katie@purecommunicationsinc.com

Voyager Therapeutics